PD-1

Padcev plus Keytruda access guide: enfortumab vedotin and pembrolizumab regimen-level coverage for urothelial cancer, HCPCS J9177/J9271 billing, pathway positioning, and PA criteria

Padcev (enfortumab vedotin-ejfv, Astellas/Pfizer) plus Keytruda (pembrolizumab, Merck) is the standard-of-care first-line regimen for...